Biogen's Alzheimer's Drug Goes From Bust to Boon, Plus Why Walgreens Is Shuttering 200 Healthcare Clinics
New data on Biogen's formerly shelved Alzheimer's disease drug puts it on a path toward blockbuster status, but it will have to win regulatory approval first.
Including one or more of these three top medical-device companies in your portfolio now could be savvy.
Slow sales of its glaucoma drugs is forcing management to cut its sales guidance.
The maker of tubeless insulin pumps continues to deliver sales growth ahead of industry watchers' outlook.
This fast-growing medical device company just reported better-than-expected results.
From small biotechs to big health insurance, and big pharma.
Is it finally time to add these three fallen biotech stocks to your portfolio?
Concerns over the pace of growth in cannabis sales are mounting.
Seattle Genetics and Amgen are the stocks to watch following this year's European Society for Medical Oncology meeting.
How vaping risks may impact cannabis companies and Aimmune Therapeutics' plan to change how doctors treat peanut allergies.
Adding these growing mid-cap companies to portfolios this month could pay off.
Patients have new hope following successful trials in dementia-related psychosis and lung cancer treatments.
Amgen is acquiring Otezla, and The Medicines Company unveils stellar data for its cholesterol treatment.
The company's most advanced drug has taken a step toward FDA approval.
Wall Street is increasingly optimistic about this medical device company.
Income-focused investors should be able to count on these companies: a fast-food giant, a media empire, and a REIT in an unusual niche.
Not every company deserves to be in your 50-year portfolio, but owning these three could pay off handsomely.
Long-term catalysts could make these top stocks a savvy addition to portfolios.
Adding these top stocks to long-haul portfolios now could be profit-friendly.
These companies are making it easier for people to find caregivers for their aging parents and young children.